<DOC>
	<DOCNO>NCT02184286</DOCNO>
	<brief_summary>The objective study determine effect nevirapine steady-state pharmacokinetics saquinavir-sgc determine effect saquinavir-sgc steady-state pharmacokinetics nevirapine . This study also evaluate pharmacokinetics nevirapine combination saquinavir-sgc compare historical control treat nevirapine without saquinavir-sgc .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Between Nevirapine Saquinavir-sgc HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>Male female patient age 18 65 year seropositive HIV1 antibody ELISA test confirm alternative method , e.g . Western blot Patients meet follow laboratory parameter : Granulocyte count ≥ 1000 cells/mm3 Hemoglobin ≥ 9.0 g ( dL ( men woman ) Platelet count ≥ 75,000 cells/mm3 Alkaline phosphatase ≤ 3.0 time upper limit normal Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) ≤ 3.0 time upper limit normal Total bilirubin ≤ 1.5 time upper limit normal Patients receive stable antiretroviral regimen , include saquinavirsgc ( Fortovase® ) 1600 mg b.i.d . 28 day prior visit 1 Female patient childbearing potential must willing use reliable form contraception , include medically approve form barrier contraception Patients able provide write informed consent comply study requirement Patients viral load le 400 copies/mL Female patient pregnant breastfeed Patients require systemic treatment corticosteroid drug know hepatic enzyme inducer inhibitor 14 day prior visit 1 . Such substance category include macrolide antibiotic ( erythromycin , clarithromycin , azithromycin , dirithromycin ) , azole antifungal ( ketoconazole , fluconazole , itraconazole ) , rifampin , rifabutin , phenytoin Patients previous exposure ( currently treat ) nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) Patients receive protease inhibitor saquinavirsgc ( Fortovase® ) 28 day prior visit 1 Patients receive investigational drug , antineoplastic agent radiotherapy local skin radiotherapy treatment 12 week prior visit 1 Patients malabsorption , severe chronic diarrhea patient unable maintain adequate oral intake Patients current history intravenous drug abuse , alcohol substance abuse ( within last year ) Patients undergoing treatment active infection Patients heavy smoker ( ≥ 20 cigarette cigar per day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>